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Abstract: The 3' end of the human T-cell leukemia/lymphoma virus type-1 (HTLV-1) 
genome  contains  four  overlapping  open  reading  frames  (ORF)  that  encode  regulatory 
proteins. Here, we review current knowledge of HTLV-1 orf-I and orf-II protein products. 
Singly spliced mRNA from orf-I encodes p12, which can be proteolytically cleaved to 
generate p8, while differential splicing of mRNA from orf-II results in production of p13 
and p30. These proteins have been demonstrated to modulate transcription, apoptosis, host 
cell  activation  and  proliferation,  virus  infectivity  and  transmission,  and  host  immune 
responses. Though these proteins are not essential for virus replication in vitro, p8, p12, 
p13, and p30 have an important role in the establishment and maintenance of HTLV-1 
infection in vivo. 
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1. Introduction 
Human  T-cell  leukemia/lymphoma  virus  type-1  (HTLV-1)  is  an  oncogenic  retrovirus  first 
discovered  in  1980  in T-cells of a patient with  cutaneous T-cell lymphoma [1,2]. HTLV-1 is the 
etiological  agent  of  two  major  diseases:  adult  T-cell  leukemia  (ATL),  a  disease  characterized  by 
malignant proliferation of CD4
+ T-lymphocytes, and tropical spastic paraparesis/HTLV-1-associated 
myelopathy (TSP/HAM), a neurodegenerative condition [3,4]. HTLV-1 is also associated with other 
clinical  disorders  including  HTLV-1-associated  arthropathy,  HTLV-1-associated  uveitis,  infective 
dermatitis, and polymyositis [5,6]. HTLV-1 primarily infects CD4
+ T-cells and has been detected in  
ex  vivo  CD8
+  T-cells,  dendritic  cells  (DC), and  B-cells  from infected  individuals. While  cell-free 
virions have been shown to efficiently infect DCs in vitro, HTLV-1 is believed to be transmitted to  
T-cells and DCs mostly by cell-to-cell contact through a virological synapse, biofilm-like extracellular 
viral  assemblies,  or  cellular  conduits  [7–10].  An  estimated  10–20  million  people  worldwide  are 
infected with HTLV-1 [11]. While the majority of HTLV-1-infected individuals remain asymptomatic, 
a low percentage of patients develop either ATL (3–5%) or TSP/HAM (0.3–2%) after a long period of 
clinical latency [12–19]. 
As shown in Figure 1, the HTLV-1 genome contains the typical retroviral structural and enzymatic 
genes gag, pro, pol, and env [13]. In addition, a region located between env and the 3' long terminal 
repeat (LTR), contains four partially overlapping open reading frames (ORF) [13]. This unique region 
encodes  several  regulatory  proteins  through  the  use  of  alternative  splicing  and  internal  initiation 
codons [20–22]. Orf-I produces the p12 protein which can be proteolytically cleaved at the amino 
terminus  to  generate  the  p8  protein,  while  differential  splicing  of  mRNA  from  orf-II  results  in 
production  of  the  p13  and  p30  proteins  [20–23].  Orf-III  and  orf-IV  encode  for  the  Rex  and  Tax 
proteins, respectively, and an antisense mRNA transcribed from the 3' LTR that generates the HTLV-1 
basic leucine zipper (HBZ) protein [24–26].  
Tax and Rex are required for viral replication. Tax is a potent transcriptional transactivator of viral 
gene expression. Tax also regulates the expression of several cellular genes, including those involved 
in  cell  proliferation,  cell  cycle  progression,  apoptosis,  and  DNA  damage  responses.  Rex  is  a  
post-transcriptional  regulator  that  facilitates  nuclear  export  of  unspliced  and  singly  spliced  viral 
mRNA. In addition, Rex inhibits splicing and transport of doubly spliced mRNA. HBZ is a negative 
regulator of Tax-mediated transactivation and thus suppresses viral expression. For further detailed 
information about Rex, Tax, and HBZ, the reader is referred to recent reviews [27–30]. In this review, 
we will focus on the current knowledge of the functions of the proteins encoded by orf-I and orf-II: p8, 
p12, p13, and p30. 
In contrast to Tax and Rex, orf-I and orf-II are dispensable for viral replication in vitro yet are 
important for viral persistence in vivo [31]. Early work demonstrated that in the rabbit model, orf-I was 
required for viral infectivity while orf-II was required to maintain high viral load [32,33]. Further work 
in the rabbit model showed reversion of HTLV-1 clones lacking p30 to the wildtype p30-expressing 
virus, suggesting the importance of p30 to HTLV-1 viral persistence [34]. However, in these early 
studies the HTLV-1 clones that were used contained a frameshift that affected hbz, making it unclear 
as to whether these effects were due to the loss of hbz or orf-I and orf-II-encoded proteins. In a more 
recent study, the ablation of p12/p8, p30, or HBZ impaired the establishment of persistent infection in Viruses 2011, 3                         
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the macaque model [35]. Nevertheless, ablation of these proteins did not affect viral replication in the 
rabbit model [35]. The orf-I and orf-II-encoded proteins are able to modulate a diverse range of viral 
and  cellular  mechanisms  including  transcriptional  regulation,  mitochondrial  function,  cell  cycle 
progression, host cell activation and proliferation, apoptosis, virus infectivity and transmission, and 
host immune responses. Though these proteins are not essential for virus replication in vitro, p8, 12, 
p13, and p30 have an important role in the establishment and maintenance of HTLV-1 infection in vivo. 
Figure  1.  A  scheme  of  the  human  T-cell  leukemia/lymphoma  virus  type-1  (HTLV-1) 
genome.  Spliced  mRNAs  and  encoded  proteins  for  orf-I  and  orf-II  are  shown.  Orf-I 
encodes for the p12 protein which can be proteolytically cleaved at the amino terminus to 
generate  the  p8  protein.  The  p30  protein  is  translated  from  doubly  spliced  mRNA 
transcribed from orf-II and the 5' end of env. The p13 protein is translated from singly 
spliced mRNA transcribed from orf-II and corresponds to the carboxyl terminus of p30. 
 
2. HTLV-1 p12 and p8 
HTLV-1 orf-I encodes the 99 amino acid p12 protein which can be proteolytically cleaved at the 
amino  terminus  to  generate  the  p8  protein  (Figure  1).  Computational  analysis  of  the  amino  acid 
sequence of p12 predict the existence of a noncanonical endoplasmic reticulum (ER) retention/retrieval 
signal between amino acids 1–5, two putative leucine zipper (LZ) motifs, two putative transmembrane 
domains between amino acids 12–30 and amino acids 48–67, a calcineurin-binding motif between amino 
acids  70–86,  four  putative  proline-rich  (PXXP)  Src  homology  3  (SH3)-binding  domains,  and  a 
putative  adaptin  motif  [23,36].  These  structural  features  may  contribute  to  protein  localization, 
homodimerization, and protein-protein interactions. The p12 protein exhibits amino acid similarity 
with a portion of the bovine papillomavirus (BPV)-transforming E5 protein, except that E5 does not 
carry  putative  SH3  binding  motifs  [37,38].  The  p12  protein  undergoes  complex  post-translational 
modifications through proteolytic cleavage. The first cleavage occurs between amino acid positions 9 Viruses 2011, 3                         
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and 10 and is followed by a second cleavage between amino acids 29 and 30 [23]. The first proteolytic 
cleavage removes the ER retention/retrieval signal at the amino terminus of p12, while the second 
cleavage  generates  the  p8  protein  [23].  The  p12  protein  localizes  to  cellular  endomembranes, 
particularly within the ER and Golgi apparatus, while p8 traffics to lipid rafts at the cell surface and is 
recruited to the immunological synapse upon T-cell receptor (TCR) ligation [23,39–41]. 
The singly spliced mRNA encoding p12/p8 has been detected in vitro and in ex vivo HTLV-1-infected 
T-cells and macrophages  [42]. The p12 recombinant protein is recognized in serum from humans 
infected with HTLV-1 and rabbits experimentally infected with HTLV-1 [43]. In addition, a cytotoxic 
T-lymphocyte (CTL) response to orf-I products can be detected in HTLV-1-infected individuals [44]. 
Two natural variants of the p12 protein have been identified; one variant carries a lysine residue at 
position 88 and is commonly found in HTLV-1 strains from TSP/HAM patients while the second 
variant carries an arginine residue at position 88 and is found in HTLV-1 strains from all ATL patients 
and healthy carriers studied. The R88 variant protein has a much greater stability compared to the K88 
variant, which is ubiquitinated and rapidly degraded by the proteasome [45]. 
2.1. T-Cell Signaling 
2.1.1. Calcium Release 
The  p12  protein  resides  in  the  endoplasmic  reticulum,  which  has  a  role  in  protein  and  lipid 
synthesis, carbohydrate metabolism, and calcium concentration regulation. Within the ER, p12 is able 
to mediate an increase in cytosolic calcium in T-cells by increasing calcium release from the ER 
through inositol trisphosphate receptors and from capacitative calcium entry through Ca
2+ channels at 
the plasma membrane in response to the lower ER calcium content (Figure 2(1)) [46,47]. By depleting 
ER calcium stores and increasing cytosolic calcium, p12 is able to modulate a range of processes 
including T-cell proliferation, viral replication, and viral spread. Early studies on orf-I showed that p12 
is able to activate nuclear factor of activated T-cells (NFAT), which is dependent on calcium-binding 
proteins for its dephosphorylation and nuclear import, to increase T-cell proliferation (Figure 2(2))  
[46–48]. Furthermore, p12 can impact other calcium-regulated proteins, including the transcriptional 
coactivator p300, which can modulate transcription of viral genes from the HTLV-1 LTR [49,50]. 
Moreover,  p12  can  promote  cell-to-cell  viral  spread  by  inducing  lymphocyte  function-associated 
antigen 1 (LFA-1) clustering on T-cells through a calcium-dependent mechanism (Figure 2(5)) [51]. 
2.1.2. NFAT Activation and Signaling 
Prior to the discovery of p12 cleavage, expression of orf-I-encoded proteins (ORF-I) was shown to 
enhance T-cell proliferation [46,51,52]. Early studies found that ORF-I was able to mediate activation 
of NFAT, a transcription factor that regulates activation, proliferation, and differentiation of T-cells 
[46–48].  In  uninfected  cells,  NFAT  can  be  activated  through  a  complex  TCR  signaling  cascade. 
Following TCR engagement at the cell surface, the protein tyrosine
 kinases Lck and Fyn phosphorylate 
TCRδ and the CD3 subunits. These phosphorylated
 domains become the docking sites for ZAP70. 
Activated ZAP70 phosphorylates linker for activation of T-cells (LAT), which then binds and activates 
phospholipase C-γ-1 (PLCγ1), leading to the production of inositol-1,4,5-trisphosphate and release of Viruses 2011, 3                         
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Ca
2+ from ER calcium stores. The increase in cytosolic calcium activates calmodulin and calcineurin, 
which dephosphorylate NFAT, allowing for NFAT nuclear import. As discussed in Section 2.1.1, by 
modulating the regulation of cytosolic calcium levels, p12 is able to mediate NFAT activation and 
does so independent of the proximal TCR signaling molecules, LAT and PLCγ1 (Figure 2(2)) [47]. 
Interestingly, p12 is able to bind calcineurin and the calcineurin-binding motif of p12 is homologous to 
the calcineurin-binding motif of NFAT (Figure 2(2)) [48]. Thus, p12 could both enhance and inhibit 
NFAT activation by competing with NFAT for calcineurin binding. Further studies found that p8, 
which localizes at the cell surface, is also able to downregulate NFAT activity, but in a LAT-dependent 
manner (Figure 2(3)) [52]. 
2.1.3. Proximal T-Cell Signaling and T-Cell Anergy 
Recent studies indicate that p8 decreases T-cell activation by inhibiting proximal T-cell receptor 
signaling [52]. Upon ligation of the TCR to the major histocompatibility complex class II (MHC-II) of 
an  antigen  presenting  cell,  p8  localizes  to  the  immunological  synapse  where  it  decreases 
phosphorylation of LAT, PLCγ1, and Vav by a LAT-dependent mechanism (Figure 2(3)) [23,52].  
By  dampening  TCR  signaling,  p8  downregulates  NFAT  activation,  a  crucial  pathway  in  T-cell 
activation  [47,52].  Furthermore,  the  induction  of  T-cell  anergy,  a  state  in  which  T-cells  become 
unresponsive  to  TCR  stimulation,  results  in  decreased  Tax  activity  and  HTLV-1  replication  [52]. 
Lastly,  since  it  has  been  recently  shown  that  p8  transfers to  neighboring  cells,  it is  possible that  
p8-induced T-cell anergy allows a safe transfer of the virus to target cells [9]. These results may 
underlie the finding that HTLV-1-infected individuals experience some immune deficiency and are 
susceptible to opportunistic infections [53,54].  
2.1.4. IL-2 Receptor Activation and STAT5 Signaling 
HTLV-1-infected T-cells proliferate in the absence of IL-2 and this IL-2 independence correlates 
with  constitutive  activation  of  the  Janus-associated  kinase  and  signal  transducer  and  activator  of 
transcription  (JAK-STAT)  pathway,  a  transcription  factor  cascade  that  affects  cell  proliferation, 
differentiation,  and  apoptosis  [55].  Early  work  showed  that  ORF-I  did  not  have  a  role  in  IL-2 
independence  since  it  did  not  affect  expression  of  the  interleukin-2  receptor  (IL-2R)  or  IL-2 
responsiveness [56]. Also, expression of ORF-I did not affect phosphorylation of JAK-STAT proteins 
[56]. However, more recent studies have demonstrated that ORF-I binds the β and γc chains of the 
immature IL-2R [57]. This interaction stabilizes the IL-2R β and γc chains in a pre-Golgi compartment 
and prevents their trafficking to the plasma membrane, leading to a decrease in IL-2R at the cell 
surface [57]. Specifically, ORF-I binds the 20 amino acid region proximal to amino acid 350 of the  
IL-2R β chain that is critical for JAK1 and JAK3 recruitment, which occurs after IL-2 signaling [58]. 
The interaction of ORF-I and IL-2R leads to an increase in STAT5 phosphorylation and DNA binding 
activity in the absence of IL-2 [58]. This effect is dependent on the presence of the β and γc chains and 
JAK3 [58]. By binding the IL-2R, ORF-I decreases the requirement of IL-2 for proliferation in T-cells 
in the presence of suboptimal antigen stimulation [58]. Viruses 2011, 3                         
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2.2. MHC-I Degradation 
HTLV-1 modulates T-cell activation and, in addition, has evolved mechanisms to avoid immune 
recognition of infected cells.  On the cell surface,  MHC-I complexes present peptides to TCRs of 
cytotoxic T-lymphocyte. In the case of virus-infected cells, this interaction leads to recognition of viral 
peptides and destruction of infected cells. Prevention of MHC-I expression is useful to a number of 
viruses to maintain the balance between the host and pathogen. Adenovirus E19 protein can retain 
MHC-I in the ER by interacting with the 1 and 2 regions of class I heavy chains through a dilysine 
motif [59]. HCMV type I membrane glycoproteins US2 and US11 target MHC-I heavy chains for 
degradation by the proteasome [60]. Additionally, HIV Nef and Vpu proteins accelerate endocytosis of 
MHC-I complexes and bind to and destabilize newly synthesized MHC-I, respectively [61–63]. In the 
ER, p12 binds to newly synthesized MHC-I heavy chains and prevents them from associating with the 
β2-microglobulin, a component of the mature MHC-I complex (Figure 2(4)) [40]. Since improperly 
assembled proteins are removed from the ER for degradation, the p12-mediated inhibition of MHC-I 
heavy chain association with the β2-microglobulin leads to its degradation by the proteasome and 
results  in  decreased  MHC-I  cell  surface  expression.  By  decreasing  antigen  presentation  through 
degradation of the MHC-I, p12 may diminish presentation of viral peptides and decrease recognition 
by cytotoxic T-lymphocytes.  
2.3. Modulation of ICAM 
Natural killer (NK) cells recognize and destroy cells that express low levels of MHC-I at the cell 
surface.  ORF-I  decreases  MHC-I  expression  to  inhibit  presentation  of  viral  proteins  to  cytotoxic  
T-lymphocytes, which could make HTLV-1-infected cells susceptible to NK cell cytotoxicity [40,64]. 
In contrast, HTLV-1-infected T-cells are resistant to NK cell-mediated killing [64]. This resistance can 
be moderately ameliorated by pretreatment of NK cells with IL-2 [64]. Early data demonstrated that 
several ATL cells lines had altered expression of intercellular cell adhesion molecule 1 (ICAM-1), a 
glycoprotein  that  facilitates  the  interaction  between  NK  cells  and  T-cells  [65].  Furthermore,  the 
majority of HTLV-1-infected primary CD4
+ T-cells do not express ligands for the NK cell activating 
receptors, natural cytotoxicity receptors, and NKG2D [64]. Recent work has elucidated these findings 
as it is now known that ORF-I decreases expression of ICAM-1 and ICAM-2, but not ICAM-3, in  
T-cells. Thus, ORF-I inhibits NK cell adhesion to T-cells and prevents virus-infected cells from being 
recognized in the presence of low levels of MHC-I [64]. 
2.4. V-ATPase 
The BPV E5 oncoprotein interacts with the 16 kDa subunit of the H
+ vacuolar ATPase (V-ATPase), 
resulting in alkalization of the Golgi apparatus [66,67]. The sequence homology between HTLV-1 
ORF-I and BPV E5 led to the demonstration that p12 interacts with 16 kDa subunit of the V-ATPase 
[68,69]. The transmembrane domains of ORF-I appear to be dispensable for binding to the V-ATPase, 
while conservation of the proline-rich domains between amino acids 36 and 48 contributes to the 
strength of this interaction [37,69]. The 16 kDa protein is a membrane component of the V-ATPase, 
which is also found in clathrin coated vesicles, lysosomes, endosomes, Golgi vesicles, endoplasmic Viruses 2011, 3                         
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reticulum,  and  synaptic  vesicles.  This  proton  pump  is  responsible  for  the  acidification  of  these 
intracellular vesicles [70]. The atypical function of the proton pump through binding of viral proteins 
such  as  HTLV-I  p12  and  BPV  E5  proteins  may  interfere  in  functions  like  the  dissociation  of  
receptor-ligand complexes and trafficking within the endosomal/lysosomal compartment. In addition, 
the acidification is essential for the formation of endosome carrier vesicles, which are intermediates 
between  early  and  late  endosomes  [71,72].  HTLV-1  is  known  to  infect  dendritic  cells  and  the 
acidification of lysosomes could play an important role in virus entry [7,73,74]. Indeed, the ablation of 
ORF-I expression impairs HTLV-1 replication in dendritic cells [35]. 
Figure 2. Functions of p12 and p8. In the ER, p12 is proteolytically cleaved at the amino 
terminus to generate p8, which traffics to the cell surface through the secretory pathway. 
(1) In the ER, p12 mediates Ca
2+ release, which enables (2) either calcineurin binding of 
NFAT and subsequent dephosphorylation, nuclear translocation, and upregulation of the 
IL-2 gene, or p12 binding to calcineurin and inhibition of NFAT activation. (3) Upon 
trafficking  through  the  secretory  pathway,  p8  localizes  at  the  immunological  synapse 
where it interacts with LAT and inhibits proximal TCR signaling. (4) In the ER, p12 binds 
the  immature  heavy  chains  of  the  MHC-I  and  prevents  their  interactions  with  the  
β2-microglobulin, leading MHC-I degradation by the proteosome. (5) At the cell surface, 
p8  increases  the  clustering  of  LFA-1  and  the  formation  of  intracellular  conduits  and 
facilitates viral transmission to target cells. 
 Viruses 2011, 3                         
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2.5. Modulation of Virus Transmission in vitro and in vivo 
HTLV-1 requires orf-I in vivo to establish a persistent viral infection [33,35]. Early studies reported 
that orf-I expression was necessary for HTLV-1 infection in the rabbit model [33]. However, these 
early studies used HTLV-1 clones that, in addition to deleting orf-I, produced a frameshift affecting 
the gene encoding HBZ. Therefore, it is unclear whether these results are due to deletion of hbz, orf-I, 
or both. More recently, HTLV-1 molecular clones with nucleotide mutations were used to selectively 
disrupt orf-I expression. This study shows orf-I is essential for infectivity in the macaque model but 
not in the rabbit model [35]. Orf-I expression in HTLV-1-infected T-cells enhances virus transmission 
to target cells [75]. Independent of IL-2, ORF-I increases chemotaxis to facilitate the migration of 
infected cells toward target cells [75]. Importantly, HTLV-1 infection requires cell-cell contact for 
efficient  transmission  through  a  virological  synapse,  biofilm-like  extracellular  viral  assemblies,  or 
cellular  conduits  [8–10,76].  Transfer  of  virus  between  cells  at  the  virological  synapse  requires 
polarization of cytoskeletal proteins and adhesion molecules toward the site of cellular contact [8]. 
Recent  evidence  suggests  that  p8,  one  of  the  two  orf-I  products,  modulates  the  clustering  of  the 
adhesion molecule LFA-1 to increase the formation of cell-cell contacts and facilitate virus transfer 
(Figure 2(5)) [9,51]. In addition, p8 promotes the formation of thin membranous cellular conduits, 
which  allows  intracellular  communication  between  several  cell  types  [9,77,78].  Through  these 
conduits, the HTLV-1 proteins p8, Gag, and Env are transferred to target T-cells [9]. Altogether, p8 
promotes cellular contacts to favor HTLV-1 transmission. 
3. HTLV-1 p30 
Initially identified in 1992, the p30 protein is translated from doubly spliced monocistronic mRNA, 
containing exons 1, 2, and B, transcribed from HTLV-1 orf-II (Figure 1) [20,21,79]. p30 is a highly 
basic protein with a net positive charge that contains three nuclear localization signals (NLS1, NLS2, 
and NLS3) located between amino acids 66–73, 91–98, and 200–241 and an arginine-rich nucleolar 
localization/retention  (NoRS)  domain  between  amino  acids  73–78  [80].  p30  also  contains  a  
Rex-binding domain (RexBD) between amino acids 131–164, a p300-binding domain between amino 
acids  1–132,  and  a  DNA-binding  domain  between  amino  acids  100–179  [81].  The  DNA-binding 
domain has been shown to repress LTR-mediated transcription [82]. Notably, HTLV-1 p30 has low 
genetic variability and is similar to HTLV-2 p28, suggesting a conserved mechanism for negative 
modulation of virus replication [79,83,84]. p30 shares distant similarities with some human serine-rich 
transcriptional activators such as Oct-1, Oct-2, Pit-1, and POU-M1 [22]. The p30 protein localizes 
within  the  nucleus  and  nucleolus.  p30  shows  high  mobility  within  the  nucleus,  yet  it  is  strongly 
retained  in  the  nucleolus.  Specifically,  p30  is  located  in  a  granular  component  where  ribosome 
subunits are assembled and de novo mRNA is produced. This localization is consistent with the ability 
of p30 to bind the ribosomal subunit L18a and to retain in the nucleus the newly transcribed tax/rex 
mRNA (Figure 3(1)) [80]. Since L18a and the eukaryotic initiation factor 3 facilitate re-initiation of 
translation in the cytoplasm, it is possible that p30 translocates from the nucleoli to the cytoplasm [80]. 
Similarly, p30 is specifically delocalized from the nucleoli to the nucleoplasm upon DNA damage to 
interfere with DNA repair processes [85]. In addition, p30 nucleolar retention signal mutants have 
similar  functionality  as  wildtype  p30,  which  raises  questions  about  the  function  of  nucleolar Viruses 2011, 3                         
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localization. A recent hypothesis suggests that p30 retention within nucleoli may serve as a reservoir 
for when the protein is needed in the nucleus [85]. Interestingly, it has recently been shown that hbz 
mRNA  can  regulate  the  production  of  p30,  probably  acting  as  an  antisense  RNA  to  silence  its 
expression (Figure 3(4)) [86]. Localization of p30 within the nucleus and nucleolus suggest that this 
protein may mediate critical cellular processes such as cell cycle progression, DNA repair, and mRNA 
export [87]. Though the main cellular target of HTLV-1 is CD4
+ T-cells, the virus is able to infect 
CD8
+ T-cells, B-cells, macrophages, and dendritic cells. Intriguingly, recent studies have shown that in 
a macaque model, ablation of p30 within the HTLV-1 provirus severely affects infectivity and leads to 
reversion of the virus to the wild type genotype [35]. This observation has been confirmed in vitro by 
p30  knockout  in  HTLV-1-infected  human  primary  and  monocyte-derived  dendritic  cells,  in  
which infection is not sustained over time. In T-cells, p30 is not required in vitro for efficient viral 
replication [35]. 
3.1. Inhibition of Nuclear Export of Tax/Rex mRNA 
In contrast to HTLV-1 Tax and Rex, which enhance viral replication, p30 promotes virus latency by 
retaining tax/rex mRNA within the nucleus to prevent its export to the cytoplasm (Figure 3(5)) [88]. 
By downregulating Tax and Rex production, p30 suppresses viral replication. p30 interacts with the 
p30  mRNA-responsive  element  (p30RE)  of  tax/rex  mRNA  and  with  Rex  at  the  RexBD  [89]. 
Interestingly, p30RE spans the exon junction created after env mRNA is spliced, hence p30 binds 
spliced tax/rex mRNA but not the unspliced and singly spliced viral RNA [81]. The interplay between 
Rex and p30 is a regulatory switch between viral replication and latency. Rex binds with high affinity 
to the Rex-responsive element (RexRE) at the 3' end of viral mRNA and, together with CRM1, shuttles 
unspliced gag/pol and singly spliced env transcripts to the cytoplasm (Figure 3(3)). Once bound to 
mRNA,  Rex  is  no  longer  accessible  to  binding  by  p30  and  is  able  to  shuttle  transcripts  to  the 
cytoplasm. However, viral mRNA-bound p30 efficiently interacts with Rex, but tax/rex transcripts are 
still retained in the nucleus (Figure 3(5)) [89]. Nuclear retention of viral mRNA is reversed by an 
excess of Rex, which displaces p30 from the p30RE. A further spliced version of tax/rex has been 
found in HTLV-infected cells, p21rex. During splicing of p21rex, the p30RE is removed from rex 
mRNA, which allows the transcript to escape p30-mediated nuclear retention. However, the function 
of p21rex is still unknown [88,90,91]. Thus, by retaining tax/rex mRNA, p30 decreases the translation 
of  these  two  positive  regulator  of  viral  replication  and  promotes  latency  to  escape  host  immune 
surveillance and to favor propagation through cell division and clonal expansion of infected cells. 
3.2 Repression of the CRE Pathway 
In  addition  to  its  posttranscriptional  activity,  p30  has  been  shown  to  function  as  either  a 
transcriptional activator or repressor. The ability of p30 to induce transcriptional activation in vitro is 
CBP/p300-dependent [92]. CBP/p300 are known binding partners of CREB and Tax and are required 
for strong activation of the viral LTR [92]. Several other cellular and viral proteins bind CBP/p300, 
including  members  of  the  Jun-family,  c-Myb,  c-Fos,  STAT1/2,  NF-κB,  p53,  and  TATA-binding 
protein (TBP) [82]. p30 disrupts CREB-Tax-p300 complex formation on the TRE (Tax-responsive 
element) of the viral LTR, resulting in repression of HTLV-1 transcription [82,93]. p30 has also been Viruses 2011, 3                         
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reported  to  differentially  regulate  transcription  from  the  viral  TRE  and  cellular  CREB-responsive 
elements (CRE) in vitro and in vivo independent of Tax expression [94,95]. While p30 has been shown 
to  repress  CRE-driven  gene  expression  in  a  dose-dependent  manner,  low  concentrations  of  p30 
enhance LTR activity [95,96]. Therefore, the expression level of p30 may play an important role in its 
function in the cell. Because p30 suppresses Tax production by retaining tax/rex mRNA in the nucleus, 
it affects CRE- and TRE-mediated transcriptional activation [88]. Interestingly, histone acetyltransferase 
(HAT) activity of p300 modulates p30-dependent transcriptional downregulation, whereas p30-dependent 
LTR repression is enhanced by deacetylation and inhibited by acetylation [82,93]. 
Figure 3. Functions of p30. (1) Alternatively double spliced mRNA is translated to form 
the Tax and Rex regulatory proteins. (2) Tax protein localizes to the nucleus to exert its 
function on the LTR as a positive regulator of viral transcription. (3) Within the nucleus, 
Rex recognizes the Rex-responsive elements (RexRE) of viral mRNA and shuttles these 
transcripts to the cytoplasm while inhibiting splicing processes. However, some of the viral 
RNA  is  processed  in  the  spliced  env  mRNA,  the  double  spliced  p30,  (4)  and  the 
alternatively spliced tax/rex mRNA. p30 mRNA is subject to negative regulation by hbz 
mRNA. Once p30 protein is produced, it translocates to the nucleus and (5) interacts with 
p30-responsive elements (p30RE) created by the double splicing and therefore is present 
on tax/rex mRNA only. Moreover, p30 interacts with Rex to inhibit Rex-mediated nuclear 
export  of  double  spliced  viral  mRNA,  including  tax  transcripts.  By  preventing  Tax 
production, p30 decreases viral transcription. 
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3.3. Transcriptional and Posttranscriptional Regulation 
Microarray gene expression analyses of human T-cells showed that HTLV-1 p30 affects a number 
of  cellular  genes  at  the  transcriptional  level.  p30  alters  expression  of  a  variety  of  gene  families 
including those that have a role in transcription, translation, cell cycle progression, DNA replication 
and repair, cell signaling, angiogenesis, cell migration, and apoptosis [97]. Furthermore, p30 is able to 
retain some cellular transcripts within the nucleus, similarly to viral tax/rex mRNA. Included among 
these transcripts are MDM4, which is a regulator of p53, and HDAC3, which is a histone deacetylases 
involved in transcriptional repression [97]. Moreover, p30 has been shown to interact with the cellular 
transcription factor PU.1 in human macrophages. PU.1 is involved in a variety of cellular pathways 
including signal transduction by Toll-like receptor-4 (TLR-4) [98]. The interaction of p30 and PU.1 
leads to inhibition of the DNA binding and transcriptional activity of PU.1. This, together with the 
p30-mediated inhibition of GSK-3β, yields decreased expression of TLR-4 at the cell surface, resulting 
in  decreased  secretion  of  pro-inflammatory  cytokines,  such  as  MCP-1,  TNF-α  and  IL-8,  and  an 
increase of the anti-inflammatory cytokine IL-10 [98]. 
3.4. Cell Cycle and DNA Repair 
Expression of p30 results in the accumulation of T-cells in the G2 phase of the cell cycle. p30 is 
able to enhance phosphorylation and activation of check point kinase 1 (Chk1). Chk1 is activated by 
ATM/ATR kinase following single strand DNA damage and results in a G2 arrest of the cell cycle 
[99]. p30 specifically binds to ataxia-telangiectasia mutated (ATM) and regulator of 20S proteasome 
activators  γ  (REGγ)  in  multiprotein  high  molecular  weight  complexes.  By  binding  to  ATM,  p30 
prolongs cell survival following DNA damage by inhibiting ATM autophosphorylation and subsequent 
activation of proteins involved in DNA repair, cell cycle check points, and apoptosis [100]. The effect 
of p30 interactions with REGγ remains to be determined. REGγ promotes formation of the REG-20S 
proteasome  complex  and  has  a  critical  role  in  a  number  of  cellular  processes,  such  as  cell  cycle 
progression and transcriptional regulation, and can degrade proteins in a ATP- and ubiquitin-independent 
manner. REGγ is localized in the nucleus where it interacts with and stabilizes p30, thereby altering 
p30 turnover [100]. In addition, p30 is able to bind to and prevent complex formation of cyclin E and 
cyclin-dependent  kinase  2  (CDK2).  Disruption  of  this  complex  prevents  phosphorylation  of 
retinoblastoma and subsequent E2F-mediated transcription, two key steps for G1/S transition [101]. By 
inhibiting cyclin E-CDK2 complex formation, p30 delays entry of cells into the S phase of the cell 
cycle. The inhibition of cell cycle progression is consistent with the observation that dendritic cells 
isolated from peripheral blood of ATL patients are unable to stimulate proliferation of CD4
+ and CD8
+ 
T-cells [102]. p30 is also able to interact with multiple proteins involved in DNA repair processes [85]. 
Upon DNA damage, p30 specifically delocalizes from the nucleolus to interact with and affect correct 
assembly of MRN complexes (Mre11-Rad50-Nbs1). MRN complexes are a key factor of DNA repair 
and contribute to homologous recombination (HR) during the S phase of the cell cycle. In contrast, 
during G1 or M phases, DNA damage is preferentially repaired by the nonconservative nonhomologous 
end  joining  (NEHJ)  pathway.  By  interacting  with  these  complexes,  p30  activates  a  shift  from 
conservative  HR  to  the  error-prone  NEHJ  pathway,  thus  favoring  an  accumulation  of  genomic Viruses 2011, 3                         
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alterations.  Overall,  these  observations  suggest  that  p30  could  contribute  to  the  accumulation  of 
mutations that are characteristic of transformed HTLV-1-infected T-cells.  
3.5. Requirement of orf-II in Viral Persistence in Animal Models 
Despite the effort of multiple laboratories to define the role of HTLV-1 p30, its exact function and 
relevance in vivo still remains elusive. It has been previously shown in vitro that the ablation of p30 
expression  does  not  affect  viral  infectivity  of  HTLV-1  in  human  primary  cells  and  that  p30  is 
dispensable for viral replication and immortalization of primary human T-lymphocytes [31,103]. It 
should be noted that the in vitro infectivity of p30-ablated HTLV-1 was not sustained over time in 
primary  dendritic  cell  [35].  Other  observations,  such  as  the  presence  of  antibodies  to  p30  during 
infection may provide evidence of the importance of p30 in vivo [32,104]. It was first shown that the 
ablation of p30 expression in vivo result is a dramatic decrease of HTLV-1 viral load in a rabbit model 
[32]. However, the mutation introduced to prematurely stop the translation of p30 affected hbz as well, 
whose ablation alone decreases viral replication [105]. By inserting an artificial 24 base pair linker 
containing a premature termination codon in the p30 ORF, a significant frameshift occurred in the 
antisense hbz ORF [32]. The consequence of this frameshift is unknown, but it most likely affected hbz 
expression.  Later  studies  have  used  different mutations  to  ablate  p30  expression  while  preserving  
hbz [35]. These in vivo studies showed that p30 is not necessary for HTLV-1 infectivity in a rabbit 
model as viral replication was not affected by p30 ablation [35]. In contrast, the mutation of p30 
severely affects virus infectivity in macaques, although a sufficient level of viral replication occurred 
to allow the reversion to wild type p30 over time [35]. 
4. HTLV-1 p13 
Differential  splicing  of  mRNA  from  HTLV-1  orf-II  results  in  production  of  the  p13  protein  
[20–22,106]. p13 is translated from singly spliced monocistronic mRNA to form a highly basic 87 
amino acid protein that corresponds to the carboxyl terminus of p30 (Figure 1) [21]. The p13 protein 
has been predicted to contain a short hydrophobic leader sequence between amino acids 1–5, an amino 
terminus  mitochondrial  targeting  signal  (MTS)  in  a  positively  charged  amphipathic  alpha  helix 
between amino acids 22–31, a transmembrane domain between amino acids 30–40, a flexible hinge 
region between amino acids 42–48, and a carboxyl terminus β-sheet hairpin structure between amino 
acids  65–75  that  is  homologous  to  an  α-bungarotoxin-binding  peptide  [107–109].  The  carboxyl 
terminus  region  contains  multiple  PXXP  motifs  that  may  mediate  Src  homology  3  (SH3)  ligand 
binding. In addition, the carboxyl terminus region contains a cryptic nuclear localization sequence 
(NLS) [80]. The p13 protein is mainly localized within the inner membrane of mitochondria [107,108]. 
However,  when  expressed  at  high  levels,  p13  is  able  to  localize  within  the  nucleus  and,  when 
coexpressed with Tax, is directed to nuclear speckles [39]. Localization of the p13 protein within 
mitochondria  and  the  nucleus  suggests  that  this  protein  may  modulate  effects  on  apoptosis  and 
transcriptional regulation (Figure 4). Viruses 2011, 3                         
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4.1. K
+ Influx, Inner Mitochondrial Membrane Potential, and Electron Transport Chain Activity 
The p13 protein was first shown to induce changes in mitochondrial morphology and distribution 
[107,108,110].  Mitochondria  of  p13-expressing  cells  are  clustered  and  have  a  rounded  ring  or 
crescent-like form that differs from the typical filamentous shape and interconnected mitochondrial 
network that occurs in normal cells. The rounded shape of mitochondria in p13-expressing cells is 
formed by osmotic swelling in response to energy-dependent uptake of monovalent cations, such as  
K
+ [107,108,110]. p13 mediates this effect by altering the inner mitochondrial membrane potential 
(Δψ)  to  change  K
+  permeability  of  these  organelles.  The  effects  of  p13  on  K
+  permeability  are  
dose-dependent  (Figure  4(1)).  At  low  concentrations,  p13  induces  mitochondrial  swelling  without 
causing  mitochondrial  depolarization  or  cytochrome  c  release  which  is  reversed  by  mitochondrial 
depolarization using protonophores. Cytochrome c is a component of the electron transport chain in 
mitochondria  and  is  involved  in  initiation  of  apoptosis.  At  higher  concentrations,  p13  induces 
irreversible  mitochondrial  swelling,  depolarization,  and  cytochrome  c  release.  The  change  in  
p13-mediated mitochondrial morphology is similar to, but distinct from, the changes induced by the 
mitochondrial  permeability  transition  pore  (MPTP),  a  large  nonspecific  channel  that  regulates 
cytochrome c release and apoptosis. 
p13-induced K
+ influx and mitochondrial membrane depolarization stimulates electron transport 
and mitochondrial respiration, which increases O2 consumption [110]. Modulation of respiratory chain 
activity by p13 is accompanied by increased mitochondrial reactive oxygen species (ROS) production 
(discussed in Section 4.3) [110,111]. Increased ROS levels, together with mitochondrial membrane 
depolarization,  decrease  the  opening  threshold  of  the  MPTP  to  promote  pro-apoptotic  signaling. 
Interestingly, at low concentrations of p13, increased electron transport chain activity dampens the 
effects of p13 on Δψ by extruding H
+ from the matrix [110]. 
4.2. Ca
2+ Homeostasis 
Changes  in  mitochondrial  Δψ  also  regulate  intracellular  Ca
2+  homeostasis  (Figure  4(2)) 
[107,110,112,113]. This effect is tightly linked to the ability of p13 to induce mitochondrial K
+ influx 
and depolarization [113]. A p13 peptide was found to induce rapid efflux of Ca
2+ from preloaded 
mitochondria [107]. Though p13 reduces mitochondrial Ca
2+ uptake, it does not significantly affect 
overall  change  in  cytosolic  Ca
2+  concentration,  suggesting  that  p13-mediated  mitochondrial 
depolarization may alter Ca
2+ concentration only locally [113]. By altering Ca
2+ homeostasis, p13 
increases the sensitivity of cells to Ca
2+-mediated stimuli [112]. Increased apoptosis is observed in 
p13-expressing cells upon treatment with C2 ceramide, which induces influx of Ca
2+ into mitochondria 
and opening of the MPTP [112]. Additionally, treatment of cells with histadine results in a rise in 
cytosolic Ca
2+ levels, leading to phosphorylation of CREB on serine 133 [112]. When p13 is expressed 
in cells treated with histadine, there is increased nuclear accumulation of phosphorylated CREB [112]. 
In  cells  with  mitochondrial  defects,  such  as  is  observed  in  p13-expressing  cells,  increased CREB 
phosphorylation has been shown to impair cell proliferation [114]. Viruses 2011, 3                         
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4.3. ROS Production 
In isolated mitochondria, p13 increases ROS production and this effect is associated with K
+ influx, 
mitochondrial membrane depolarization, and activation of the electron transport chain (Figure 4(3)) 
[110,111].  Unexpectedly,  in  transformed  T-cells  cultured  using  standard  conditions,  p13  does  not 
increase  ROS  production  [111].  However,  in  response to  glucose  deprivation, p13 increases  ROS 
production  and  cell  death  in  these  cells  [111].  There  is  a  distinct  gradient  of  ROS  accumulation 
between primary and transformed T-cells, with very low levels observed in resting cells, higher levels 
in  stimulated  cells,  and  substantially  higher  levels  in  transformed  cells  [111].  In  contrast  to  the  
effects  of  p13  on  transformed  T-cells,  expression  of  p13  in  unstimulated  primary  T-cells  induces  
ROS-dependent  T-cell  activation  and  proliferation  [111].  Thus,  by  increasing  mitochondrial  ROS 
production,  p13  mediates  activation  of  primary  resting  T-cells  while  promoting  cell  death  in 
transformed T-cells. By modulating ROS levels in T-cells, it is possible that p13 has a role in lifelong 
persistence  of  HTLV-1  in  the  host  by  increasing  the  pool  of  untransformed  infected  cells  while 
decreasing the number of transformed cells. 
4.4. Effects on Apoptosis 
Expression of p13 reduces proliferation rates of transformed cells in vitro and tumor growth in vivo. 
As discussed in Section 4.1, MPTP-mediated mitochondrial swelling and altered permeability has a 
key  role  in  inducing  apoptosis.  Though  p13  triggers  similar  effects  as  the  MPTP,  in  addition  to 
inducing cristae fragmentation, it does not directly cause apoptosis or cytochrome c release [108]. 
Instead, p13 increases cell sensitivity to pro-apoptotic stimuli such as Fas ligand (FasL), C2 ceramide, 
and glucose deprivation [111,115]. The effects of p13 on FasL-mediated apoptosis are enhanced by 
overexpression  of  Ras  and  antagonized  by  inhibiting  Ras  farnesylation  and  subsequent  activation 
[115]. Upon FasL stimulation, farnesylated Ras traffics to mitochondria and directly binds Bcl-2 to 
inhibit the anti-apoptotic effects of Bcl-2 [115]. Treatment of p13-expressing cells with C2 ceramide 
results in increased influx of Ca
2+ into mitochondria followed by opening of the MPTP, leading to cell 
death [111]. During glucose deprivation, p13 promotes apoptosis by increasing ROS production in 
transformed  T-cells  [111].  Consistent  with  the  central  role  of  mitochondria  in  energy  production, 
cation flux, and apoptosis, p13 is able to affect this organelle to influence cell turnover. 
4.5. Nuclear Effects 
In cells expressing Tax, p13 becomes ubiquitinated and is partially localized within the nucleus 
(Figure 4(4)) [116]. Interestingly, Tax mediates ubiquitination of p13 though this protein contains no 
lysine  residues.  Instead,  p13  is  likely  ubiquitinated  on  serine  and  threonine  residues  and  this 
modification increases the stability of the protein. Within the nucleus, ubiquitinated p13 associates 
with  Tax  to  inhibit  its  binding  to  the  CBP/p300  transcriptional  coactivator  [116].  A  decrease  in  
Tax-CBP/p300 complex formation results in decreased Tax-mediated viral gene transcription [116]. 
Thus, intracellular localization of p13 may be an additional regulatory switch between viral replication 
and latency. Viruses 2011, 3                         
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Figure 4. Functions of p13. In mitochondria, p13 mediates (1) K
+ influx, inner mitochondrial 
membrane potential, and electron transport chain activity to affect (2) Ca
2+ signaling and 
(3) ROS production. (4) In the presence of Tax, p13 is ubiquitinated and translocates to the 
nucleus.  In  the  nucleus,  p13  inhibits  Tax-CBP/p300  complex  formation  to  decrease 
transcription of cellular and viral genes. 
 
4.6. In Vivo Animal Model 
CTLs and antibodies that recognize orf-II peptides can be detected in HTLV-1-infected individuals, 
suggesting that p13 may have an important role in vivo [104,117]. In an early study to examine the role 
of p13 alone in vivo, a molecular clone of HTLV-1 mutated to selectively ablate p13 failed to establish 
viral infection in a rabbit model  [118]. However, similar to the rabbit model studies discussed in 
Sections 2.5 and 3.5, it is unknown whether the mutation that ablated p13 also affected expression of 
HBZ since the amino acid change that ablated the start codon for p13 in this study would also affect 
the start codon for HBZ [118]. No studies have been completed that examine the role of p13 alone in 
the macaque model. 
5. Conclusions 
HTLV-1-associated diseases have long periods of clinical latency with infected individuals having 
life-long persistence of viral-infected T-cell clones. Thus, HTLV-1-infected T-cells must be able to 
avoid immune recognition. As transcription of the provirus could lead to antigen presentation and 
immune recognition, it is necessary for HTLV-1 to maintain low levels of virus replication. In vivo Viruses 2011, 3                         
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studies demonstrate that HTLV-1 requires orf-I and orf-II for viral persistence. Since these proteins 
play critical roles in T-cell activation, MHC-I trafficking, cytokine expression, and virus replication, 
they are likely crucial for HTLV-1 maintenance of low level of virus expression in vivo. Together, p12 
and p8 decrease ICAM-1, ICAM-2, and MHC-I expression at the cell surface, limiting the ability of 
NK cells and CTL cells to recognize infected cells. In addition, p8 inhibits proximal TCR signaling 
upon TCR stimulation to prevent T-cell activation. In contrast, within the ER, p12 promotes Ca
2+ 
release  and  NFAT  activation  in  resting  cells.  Thus,  p12  decreases  the  IL-2  requirement  for 
proliferation in the presence of suboptimal antigen presentation. Altogether, these data suggest that the 
concerted  expression  of  p12  and  p8  modulate  T-cell  activation  and  antigen  presentation  while 
promoting  proliferation  of  resting  cells,  therefore  providing  new  target  cells  for  the  virus.  Orf-II 
protects HTLV-1-infected cells from immune system recognition by dampening the transcriptional 
effects of Tax. In the nucleus, p30 binds and prevents export of tax/rex mRNA to the cytosol for 
translation and p13, upon ubiquitination, inhibits Tax-CBP/p300 complex formation. This results in a 
decrease in the transcriptional activity of Tax and subsequent virus replication. In macrophages, p30 
favors the production of anti-inflammatory IL-10 while decreasing the expression of pro-inflammatory 
cytokines  by  interacting  with  the  transcription  factor  PU.1.  Furthermore,  like  orf-I,  p30  and  p13 
promote proliferation of resting T-cells. p30 inhibits DNA repair mechanisms to favor the growth and 
persistence of infected cells. p13 modulates the production of ROS and proliferation of resting cells 
while  promoting  apoptosis  of  transformed  cells.  The  understanding  of  how  these  proteins 
simultaneously protect HTLV-1-infected cells from destruction and promote their expansion leads to 
new questions. Where, when, and at what level these proteins are  expressed in vivo still must be 
elucidated.  The  answers  to  these  questions  will  indicate  whether  these  proteins  may  provide  new 
targets for HTLV-1 therapeutics. 
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